2017 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson's Research
11th Annual Parkinson's Disease Therapeutics Conference
October 30, 2017

New York, NY

CONFERENCE PROGRAM

All presentations are followed by Q&A.

7:45	BREAKFAST
8:30 - 9:00	WELCOME BY TODD SHERER, PhD AND DAVID STANDAERT, PhD
9:00 - 10:40	EMERGING TARGETS ADVANCING TREATMENTS
	TRENT MARTIN WOODRUFF, PhD, The University of Queensland "Therapeutic Targeting of the NLRP3 Inflammasome for Parkinson's Disease"
	PAUL THOMPSON, PhD, Mission Therapeutics Inc. "Validation of USP30 as a Therapeutic Target for Parkinson's Disease Modification"
	DARREN MOORE, PhD, Van Andel Research Institute "VPS35 as a Novel Target for Parkinson's Disease: Models and Mechanisms"
	DAVID SULZER, PhD, Columbia University "Roles for Autoimmunity in Parkinson's Disease"
10:40- 11:10	NETWORKING BREAK/POSTER VIEWING
11:10 - 12:00	PROGRESS IN THE PIPELINE
	THOMAS FOLTYNIE, PhD, MD, MRCO, University College London "Exenatide as a Treatment for Patients with Parkinson's Disease"
	BERNARD RAVINA, MD, MS, Voyager Therapeutics "AADC Gene Therapy for Advanced Parkinson's Disease"



12:00 - 1:00 LUNCH/POSTER VIEWING

1:00 - 2:15 TRACKING PROGRESS IN TRACKING PARKINSON'S

EDILIO BORRONI, PhD, F. Hoffman-LaRoche

"Development of PET Tracers for Imaging of Alpha-synuclein Aggregates"

BRIT MOLLENHAUER, MD, Paracelsus-Elena-Klinik

"Biological Analyses of PPMI Samples"

ANDREW SINGLETON, PhD, NIH National Institute on Aging

"Data Driven Analyses in PPMI"

2:15 – 2:45 NETWORKING BREAK/POSTER VIEWING

2:45 - 4:00 HOT TOPICS IN PARKINSON'S DISEASE RESEARCH

D. JAMES SURMEIER, PhD, Feinberg School of Medicine, Northwestern University

"Therapeutic Implications of Selective Neuronal Vulnerability in Parkinson's Disease"

THOMAS GASSER, MD, PhD, University of Tubingen

"Linking Parkinson's Disease Genetic Targets within Idiopathic Parkinson's Disease"

4:00 - 4:15 CLOSING REMARKS

4:15 - 6:00 COCKTAIL RECEPTION/POSTER VIEWING

